Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: The Alliance A031203 CABOSUN Trial - Choueiri, T K; Halabi, S; Sanford, B L (J Clin Oncol, 2017)
et al.